Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

'What Else Don't We Know?' May Spread Beyond Valeant

This article was originally published in Scrip

Executive Summary

The day after a damning report from short-selling firm Citron Research sent shares of Valeant Pharmaceuticals International Inc. into tailspin, diving 40%, the stock spiraled down again, plunging 20% – this time pushed off the cliff by BMO Nesbitt Burns Inc. analyst Alex Arfaei, who started off the day by asking "What else is out there that we don't know?"

Advertisement

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC030128

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel